Angela R Bradbury

List of Publications by Year
in descending order

86 papers	3,136 citations	236925 25 h-index	175258 52 g-index
88 all docs	88 docs citations	88 times ranked	5733 citing authors

#	Article	IF	Citations
1	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. Journal of Clinical Oncology, 2015, 33, 3660-3667.	1.6	603
2	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
3	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
4	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
5	Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. Genetics in Medicine, 2015, 17, 630-638.	2.4	128
6	How Often Do BRCA Mutation Carriers Tell Their Young Children of the Family's Risk for Cancer? A Study of Parental Disclosure of BRCA Mutations to Minors and Young Adults. Journal of Clinical Oncology, 2007, 25, 3705-3711.	1.6	84
7	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	2.4	82
8	Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. Genetics in Medicine, 2015, 17, 485-492.	2.4	79
9	Utilizing Remote Real-Time Videoconferencing to Expand Access to Cancer Genetic Services in Community Practices: A Multicenter Feasibility Study. Journal of Medical Internet Research, 2016, 18, e23.	4.3	79
10	Genetic susceptibility to breast cancer. Reviews in Endocrine and Metabolic Disorders, 2007, 8, 255-267.	5.7	78
11	Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing. Genetics in Medicine, 2016, 18, 25-33.	2.4	56
12	Learning of your parent's BRCA mutation during adolescence or early adulthood: a study of offspring experiences. Psycho-Oncology, 2009, 18, 200-208.	2.3	46
13	When parents disclose BRCA1/2 test results: Their communication and perceptions of offspring response. Cancer, 2012, 118, 3417-3425.	4.1	46
14	Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers. Clinical Cancer Research, 2019, 25, 1786-1794.	7.0	44
15	Multiplex genetic testing: reconsidering utility and informed consent in the era of next-generation sequencing. Genetics in Medicine, 2015, 17, 97-98.	2.4	41
16	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
17	Comparison of Clinical, Maternal, and Self Pubertal Assessments: Implications for Health Studies. Pediatrics, 2016, 138, .	2.1	36
18	Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome. Breast Cancer Research and Treatment, 2020, 181, 181-188.	2.5	36

#	Article	IF	Citations
19	Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results. Journal of the National Cancer Institute, 2018, 110, 985-993.	6.3	35
20	Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2008, 148C, 70-77.	1.6	34
21	Perspectives of Patients With Cancer on the Ethics of Rapid-Learning Health Systems. Journal of Clinical Oncology, 2017, 35, 2315-2323.	1.6	34
22	Correlation of DNA methylation levels in blood and saliva DNA in young girls of the LEGACY Girls study. Epigenetics, 2014, 9, 929-933.	2.7	32
23	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	6.3	30
24	Are Patients With Cancer Less Willing to Share Their Health Information? Privacy, Sensitivity, and Social Purpose. Journal of Oncology Practice, 2015, 11, 378-383.	2.5	29
25	Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer. Clinical Cancer Research, 2019, 25, 2072-2079.	7.0	29
26	Implementation and outcomes of telephone disclosure of clinical BRCA1/2 test results. Patient Education and Counseling, 2013, 93, 413-419.	2.2	26
27	Development of a Communication Protocol for Telephone Disclosure of Genetic Test Results for Cancer Predisposition. JMIR Research Protocols, 2014, 3, e49.	1.0	26
28	Knowledge and perceptions of familial and genetic risks for breast cancer risk in adolescent girls. Breast Cancer Research and Treatment, 2012, 136, 749-757.	2.5	24
29	The Advantages and Challenges of Testing Children for Heritable Predisposition to Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 251-269.	3.8	24
30	The LEGACY Girls Study. Epidemiology, 2016, 27, 438-448.	2.7	24
31	Research participantsâ€™ experiences with return of genetic research results and preferences for webâ€based alternatives. Molecular Genetics & Genomic Medicine, 2019, 7, e898.	1.2	24
32	Controversies in Communication of Genetic Risk for Hereditary Breast Cancer. Breast Journal, 2009, 15, S25-S32.	1.0	23
33	Effect of Public Deliberation on Patient Attitudes Regarding Consent and Data Use in a Learning Health Care System for Oncology. Journal of Clinical Oncology, 2019, 37, 3203-3211.	1.6	20
34	Patient Perspectives on the Ethical Implementation of a Rapid Learning System for Oncology Care. Journal of Oncology Practice, 2017, 13, e163-e175.	2.5	19
35	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	6.4	19
36	Pubertal development in girls by breast cancer family history: the LEGACY girls cohort. Breast Cancer Research, 2017, 19, 69.	5.0	18

#	Article	IF	Citations
37	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	2.5	18
38	Possible barriers for genetic counselors returning actionable genetic research results across state lines. Genetics in Medicine, 2017, 19, 1202-1204.	2.4	17
39	Psychosocial Adjustment and Perceived Risk Among Adolescent Girls From Families With BRCA1/2 or Breast Cancer History. Journal of Clinical Oncology, 2016, 34, 3409-3416.	1.6	16
40	Preferences for inâ€person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study. Clinical Genetics, 2019, 95, 293-301.	2.0	16
41	Returning Individual Genetic Research Results to Research Participants: Uptake and Outcomes Among Patients With Breast Cancer. JCO Precision Oncology, 2018, 2, 1-24.	3.0	15
42	Prepubertal Internalizing Symptoms and Timing of Puberty Onset in Girls. American Journal of Epidemiology, 2021, 190, 431-438.	3.4	14
43	Randomized study of remote telehealth genetic services versus usual care in oncology practices without genetic counselors. Cancer Medicine, 2021, 10, 4532-4541.	2.8	14
44	Psychosocial Adjustment in School-age Girls With a Family History of Breast Cancer. Pediatrics, 2015, 136, 927-937.	2.1	13
45	Ethical Implications of Direct-to-Consumer Hereditary Cancer Tests. JAMA Oncology, 2018, 4, 1327.	7.1	13
46	Pediatric reporting of genomic results study (PROGRESS): a mixed-methods, longitudinal, observational cohort study protocol to explore disclosure of actionable adult- and pediatric-onset genomic variants to minors and their parents. BMC Pediatrics, 2020, 20, 222.	1.7	11
47	A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOGâ€ACRIN Cancer Research Group (EAQ152). Cancer, 2022, 128, 1381-1391.	4.1	11
48	Breast cancer family history and allele-specific DNA methylation in the legacy girls study. Epigenetics, 2018, 13, 240-250.	2.7	10
49	Use and Patient-Reported Outcomes of Clinical Multigene Panel Testing for Cancer Susceptibility in the Multicenter Communication of Genetic Test Results by Telephone Study. JCO Precision Oncology, 2018, 2, 1-12.	3.0	10
50	How Should Patients and Providers Interpret the US Food and Drug Administrationâ€™s Regulatory Language for Direct-to-Consumer Genetic Tests?. Journal of Clinical Oncology, 2019, 37, 2514-2517.	1.6	10
51	Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy. Cancer, 2019, 125, 2762-2771.	4.1	10
52	Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study. Breast Cancer Research, 2020, 22, 138.	5.0	10
53	Comparison of methods to assess onset of breast development in the LEGACY Girls Study: methodological considerations for studies of breast cancer. Breast Cancer Research, 2018, 20, 33.	5.0	9
54	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. JCO Precision Oncology, 2020, 4, 916-925.	3.0	9

#	Article	IF	Citations
55	Controversies in Communication of Genetic Screening Results for Cancer: A Report from the American Society of Preventive Oncology's Screening Special Interest Group (ASPO's 33rd Annual) Tj ETQq1 1 0.784314 rgBT /Overlock 624-627.	2.5	8
56	Patient Preferences Regarding Informed Consent Models for Participation in a Learning Health Care System for Oncology. JCO Oncology Practice, 2020, 16, e977-e990.	2.9	8
57	Association of Prepubertal and Adolescent Androgen Concentrations With Timing of Breast Development and Family History of Breast Cancer. JAMA Network Open, 2019, 2, e190083.	5.9	7
58	Evaluating Web-Based Direct-to-Consumer Genetic Tests for Cancer Susceptibility. JCO Precision Oncology, 2020, 4, 161-169.	3.0	7
59	Longitudinal outcomes with cancer multigene panel testing in previously tested BRCA1/2 negative patients. Clinical Genetics, 2020, 97, 601-609.	2.0	7
60	Disclosing Genetic Risk of Alzheimerâ€™s Disease to Cognitively Unimpaired Older Adults: Findings from the Study of Knowledge and Reactions to APOE Testing (SOKRATES II). Journal of Alzheimer's Disease, 2021, 84, 1015-1028.	2.6	7
61	Bringing Alzheimer Disease Testing and Results Disclosure Into the 21st Century Cures Act. JAMA Neurology, 2022, 79, 219.	9.0	6
62	Human Subjects Protection: An Event Monitoring Committee for Research Studies of Girls From Breast Cancer Families. Journal of Adolescent Health, 2014, 55, 352-357.	2.5	5
63	Governance of a Learning Health Care System for Oncology: Patient Recommendations. JCO Oncology Practice, 2021, 17, e479-e489.	2.9	5
64	EUS-based Pancreatic Cancer Surveillance in BRCA1/BRCA2/PALB2/ATM Carriers Without a Family History of Pancreatic Cancer. Cancer Prevention Research, 2021, 14, 1033-1040.	1.5	5
65	The Need to Improve the Clinical Utility of Direct-to-Consumer Genetic Tests. JAMA - Journal of the American Medical Association, 2020, 323, 1443.	7.4	5
66	Implementing cost transparency in oncology: A qualitative study of barriers, facilitators, and patient preferences.. Journal of Clinical Oncology, 2017, 35, 6597-6597.	1.6	5
67	Longitudinal follow-up after telephone disclosure in the randomized COGENT study. Genetics in Medicine, 2020, 22, 1401-1406.	2.4	4
68	Preventative Health and Risk Behaviors Among Adolescent Girls With and Without Family Histories of Breast Cancer. Journal of Adolescent Health, 2019, 64, 116-123.	2.5	3
69	Patient Experiences, Trust, and Preferences for Health Data Sharing. JCO Oncology Practice, 2022, 18, e339-e350.	2.9	2
70	O4â€08â€03: PSYCHOSOCIAL OUTCOMES OF APOE E4ÂGENOTYPE DISCLOSURE IN THE GENERATION STUDY. Alzheimer's and Dementia, 2018, 14, P1422.	0.8	1
71	Utilization of Complementary Alternative Medicine, Diet, and Exercise Among Women at High Risk for Developing Breast Cancer. Integrative Cancer Therapies, 2020, 19, 153473542092261.	2.0	1
72	Characteristics of high risk breast cancer patients with mutations identified by multiplex panel testing.. Journal of Clinical Oncology, 2015, 33, 1511-1511.	1.6	1

#	Article	IF	Citations
73	Impact of prior knowledge of mutation status on tumor stage in BRCA1/2 mutation carriers with newly diagnosed breast cancer.. Journal of Clinical Oncology, 2015, 33, 1562-1562.	1.6	1
74	Uptake of genetic testing and outcomes in a randomized study of remote genetic services as compared to usual care in community practices without genetic providers.. Journal of Clinical Oncology, 2018, 36, 6506-6506.	1.6	1
75	Maternal and prenatal factors and age at thelarche in the LEGACY Girls Study cohort: implications for breast cancer risk. International Journal of Epidemiology, 2023, 52, 272-283.	1.9	1
76	F3-03-02: Applying lessons learned from remote genetic counseling in breast cancer to Alzheimer's disease. , 2015, 11, P214-P215.		0
77	F4â€02â€01: Connect 4 APOE: A Randomized Study of Phone Versus Videoconference Delivery of APOE Genotype Disclosure in the Generation Study. Alzheimer's and Dementia, 2016, 12, P324.	0.8	0
78	Reply to Patel and McLeod. Journal of Clinical Oncology, 2020, 38, 284-284.	1.6	0
79	Association between financial relationships with commercial interests and researchÂmerit at the ASCO Annual Meeting (AM).. Journal of Clinical Oncology, 2012, 30, 6095-6095.	1.6	0
80	Financial relationships with commercial interests (COI) among abstracts at the ASCO Annual Meeting.. Journal of Clinical Oncology, 2012, 30, 6128-6128.	1.6	0
81	Interest in and outcomes with return of individual genetic research results for inherited susceptibility to breast cancer.. Journal of Clinical Oncology, 2015, 33, e12503-e12503.	1.6	0
82	Patient-reported outcomes in a multicenter randomized study of in-person versus telephone disclosure of genetic test results for cancer susceptibility.. Journal of Clinical Oncology, 2016, 34, 1502-1502.	1.6	0
83	Extended follow-up in the COGENT study: A randomized study of in-person versus telephone disclosure of cancer genetic test results.. Journal of Clinical Oncology, 2017, 35, 1504-1504.	1.6	0
84	Knowledge outcomes in a randomized trial of telephone vs. in-person disclosure of genetic testing: The COGENT study.. Journal of Clinical Oncology, 2017, 35, 1534-1534.	1.6	0
85	Interest in and outcomes with web-based education for return of genetic research results for inherited susceptibility to breast cancer.. Journal of Clinical Oncology, 2018, 36, 1531-1531.	1.6	0
86	Risk of pediatric malignancy in families known to carry BRCA1/2 mutations.. Journal of Clinical Oncology, 2018, 36, 1535-1535.	1.6	0